{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:55:45Z","timestamp":1793123745365,"version":"4.5.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T00:00:00Z","timestamp":1732752000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This work was supported by the National Institute for Health Research Integrated Academic Training scheme (JM)."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Griscelli syndrome type 2 (GS2) is a rare, life-threatening immunodysregulatory disorder characterised by impaired cytotoxic activity leading to susceptibility to haemophagocytic lymphohistiocytosis (HLH) and hypopigmentation. We completed a literature review and analysis of clinical data of 149 patients with GS2 including 8 new patients.<\/jats:p>\n                  <jats:p>\n                    We identified three founder mutations which show diverse phenotypic profiles (\n                    <jats:italic>RAB27A<\/jats:italic>\n                    c.244\u00a0C\u2009&gt;\u2009T, p.R82C, c.514_518delCAAGC, p.Q172NfsX2, c.550\u00a0C\u2009&gt;\u2009T, p.R184X). The most common presentation was HLH (119\/149, 80%), with high proportion of central nervous system involvement (68\/149, 46%). Features of partial albinism were present in 105 of 149 cases (70%). Hypopigmentation can be absent in GS2 and should not exclude the diagnosis. Patients with biallelic protein truncating variants (PTV) were more likely to have systemic HLH (44\/56, 79%) and partial albinism (45\/56, 80%), in comparison to hypomorphic variants (9\/41, 22%; 20\/41, 49%). Patients with hypomorphic variants presented later (5.4 years cf. 0.4 years,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u2009&lt;\u20090.0001) and were more likely to have isolated CNS HLH (2% cf. 42%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.001).\n                  <\/jats:p>\n                  <jats:p>Mortality was high in the cohort (50\/149, 34%). Survival of cases post-HLH who underwent transplantation is superior to un-transplanted patients, suggesting adequate HLH control followed by early HSCT is highly beneficial. Mortality was reduced in HSCT recipients versus the un-transplanted group where follow-up data was available (14% compared to 58%).<\/jats:p>\n                  <jats:p>Asymptomatic cases identified through family history\/genetic screening may benefit from pre-emptive HSCT, but access and development of robust functional testing are required. High mortality related to HLH remains concerning and emphasises the need for improved molecular characterisation and clinical prognostic factors to guide management decisions.<\/jats:p>","DOI":"10.1007\/s10875-024-01842-2","type":"journal-article","created":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T02:48:51Z","timestamp":1732762131000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Griscelli Syndrome Type 2: Comprehensive Analysis of 149 New and Previously Described Patients with RAB27A Deficiency"],"prefix":"10.1007","volume":"45","author":[{"given":"Jesmeen","family":"Maimaris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriel","family":"Roa-Bautista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahreen","family":"Sohail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cugno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Chenchara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawfeg Ben","family":"Omran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael","family":"Hacohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Gilmour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gillian","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanchan","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Elfeky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike","family":"Kusters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,28]]},"reference":[{"issue":"10","key":"1842_CR1","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1111\/j.1365-4362.1978.tb05980.x","volume":"17","author":"C Griscelli","year":"1978","unstructured":"Griscelli C, Prunieras M. Pigment dilution and immunodeficiency: a new syndrome. Int J Dermatol. 1978;17(10):788\u201391.","journal-title":"Int J Dermatol"},{"issue":"6","key":"1842_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/MPH.0000000000001522","volume":"41","author":"A Russ","year":"2019","unstructured":"Russ A, et al. Griscelli Type 2 syndrome and Hemophagocytic Lymphohistiocytosis: sisters with the same mutation but different presentations. J Pediatr Hematol Oncol. 2019;41(6):473\u20137.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"1842_CR3","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/76024","volume":"25","author":"G M\u00e9nasch\u00e9","year":"2000","unstructured":"M\u00e9nasch\u00e9 G, et al. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet. 2000;25(2):173\u20136.","journal-title":"Nat Genet"},{"issue":"17","key":"1842_CR4","doi-asserted-by":"publisher","first-page":"15373","DOI":"10.1074\/jbc.M212341200","volume":"278","author":"M Fukuda","year":"2003","unstructured":"Fukuda M. Distinct Rab binding specificity of Rim1, Rim2, rabphilin, and Noc2. Identification of a critical determinant of Rab3A\/Rab27A recognition by Rim2. J Biol Chem. 2003;278(17):15373\u201380.","journal-title":"J Biol Chem"},{"issue":"18","key":"1842_CR5","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1007\/s00018-008-8351-4","volume":"65","author":"M Fukuda","year":"2008","unstructured":"Fukuda M. Regulation of secretory vesicle traffic by Rab small GTPases. Cell Mol Life Sci. 2008;65(18):2801\u201313.","journal-title":"Cell Mol Life Sci"},{"key":"1842_CR6","doi-asserted-by":"publisher","first-page":"612977","DOI":"10.3389\/fimmu.2020.612977","volume":"11","author":"Y Ohishi","year":"2020","unstructured":"Ohishi Y, et al. Griscelli Syndrome type 2 sine albinism: unraveling Differential RAB27A Effector Engagement. Front Immunol. 2020;11:612977.","journal-title":"Front Immunol"},{"issue":"1","key":"1842_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ncb2000","volume":"12","author":"M Ostrowski","year":"2010","unstructured":"Ostrowski M, et al. Rab27a and Rab27b control different steps of the exosome secretion pathway. Nat Cell Biol. 2010;12(1):19\u201330. sup pp 1\u201313.","journal-title":"Nat Cell Biol"},{"key":"1842_CR8","doi-asserted-by":"crossref","unstructured":"Wang Y et al. The regulation of exosome generation and function in physiological and pathological processes. Int J Mol Sci, 2023. 25(1).","DOI":"10.3390\/ijms25010255"},{"issue":"4","key":"1842_CR9","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1083\/jcb.152.4.825","volume":"152","author":"JC Stinchcombe","year":"2001","unstructured":"Stinchcombe JC, et al. Rab27a is required for regulated secretion in cytotoxic T lymphocytes. J Cell Biol. 2001;152(4):825\u201334.","journal-title":"J Cell Biol"},{"issue":"13","key":"1842_CR10","doi-asserted-by":"publisher","first-page":"5052","DOI":"10.1182\/blood-2008-02-141069","volume":"112","author":"G M\u00e9nasch\u00e9","year":"2008","unstructured":"M\u00e9nasch\u00e9 G, et al. A newly identified isoform of Slp2a associates with Rab27a in cytotoxic T cells and participates to cytotoxic granule secretion. Blood. 2008;112(13):5052\u201362.","journal-title":"Blood"},{"issue":"2","key":"1842_CR11","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.jaci.2015.12.1337","volume":"138","author":"P Netter","year":"2016","unstructured":"Netter P, et al. A novel Rab27a mutation binds melanophilin, but not Munc13-4, causing immunodeficiency without albinism. J Allergy Clin Immunol. 2016;138(2):599\u2013e6013.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1842_CR12","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.jaci.2014.08.039","volume":"135","author":"V Cetica","year":"2015","unstructured":"Cetica V, et al. Patients with Griscelli syndrome and normal pigmentation identify RAB27A mutations that selectively disrupt MUNC13-4 binding. J Allergy Clin Immunol. 2015;135(5):1310\u2013e81.","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"1842_CR13","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s10875-022-01315-4","volume":"42","author":"TCE Zondag","year":"2022","unstructured":"Zondag TCE, et al. Novel RAB27A variant Associated with late-onset Hemophagocytic Lymphohistiocytosis alters effector protein binding. J Clin Immunol. 2022;42(8):1685\u201395.","journal-title":"J Clin Immunol"},{"issue":"1","key":"1842_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12969-015-0043-7","volume":"13","author":"M Cruikshank","year":"2015","unstructured":"Cruikshank M, et al. Screening assays for primary haemophagocytic lymphohistiocytosis in children presenting with suspected macrophage activation syndrome. Pediatr Rheumatol. 2015;13(1):48.","journal-title":"Pediatr Rheumatol"},{"issue":"12","key":"1842_CR15","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.1182\/blood-2011-08-374199","volume":"119","author":"YT Bryceson","year":"2012","unstructured":"Bryceson YT, et al. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood. 2012;119(12):2754\u201363.","journal-title":"Blood"},{"key":"1842_CR16","first-page":"75","volume":"29","author":"Z Sefsafi","year":"2018","unstructured":"Sefsafi Z, et al. Macrophage activation syndrome associated with griscelli syndrome type 2: case report and review of literature. Pan Afr Med J. 2018;29:75.","journal-title":"Pan Afr Med J"},{"issue":"4","key":"1842_CR17","doi-asserted-by":"publisher","first-page":"101515","DOI":"10.1016\/j.berh.2020.101515","volume":"34","author":"G Griffin","year":"2020","unstructured":"Griffin G, Shenoi S, Hughes GC. Hemophagocytic lymphohistiocytosis: an update on pathogenesis, diagnosis, and therapy. Best Pract Res Clin Rheumatol. 2020;34(4):101515.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"1842_CR18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/bjh.14147","volume":"174","author":"E Brisse","year":"2016","unstructured":"Brisse E, Wouters CH, Matthys P. Advances in the pathogenesis of primary and secondary haemophagocytic lymphohistiocytosis: differences and similarities. Br J Haematol. 2016;174(2):203\u201317.","journal-title":"Br J Haematol"},{"issue":"23","key":"1842_CR19","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1182\/blood.2018894618","volume":"133","author":"P La Ros\u00e9e","year":"2019","unstructured":"La Ros\u00e9e P, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465\u201377.","journal-title":"Blood"},{"issue":"17","key":"1842_CR20","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1182\/blood-2011-06-356261","volume":"118","author":"H Trottestam","year":"2011","unstructured":"Trottestam H, et al. Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011;118(17):4577\u201384.","journal-title":"Blood"},{"issue":"25","key":"1842_CR21","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","volume":"130","author":"E Bergsten","year":"2017","unstructured":"Bergsten E, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017;130(25):2728\u201338.","journal-title":"Blood"},{"issue":"2","key":"1842_CR22","doi-asserted-by":"publisher","first-page":"279","DOI":"10.4103\/IJPM.IJPM_645_18","volume":"62","author":"D Gupta","year":"2019","unstructured":"Gupta D, et al. Hematopoietic stem cell transplantation in children with Griscelli syndrome type 2: experience and outcomes. Indian J Pathol Microbiol. 2019;62(2):279\u201382.","journal-title":"Indian J Pathol Microbiol"},{"issue":"12","key":"1842_CR23","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/sj.bmt.1703567","volume":"29","author":"M Aric\u00f2","year":"2002","unstructured":"Aric\u00f2 M, et al. Successful treatment of Griscelli syndrome with unrelated donor allogeneic hematopoietic stem cell transplantation. Bone Marrow Transpl. 2002;29(12):995\u20138.","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"1842_CR24","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12887-021-02720-1","volume":"21","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, et al. Successful rescue of a lethal Griscelli syndrome type 2 presenting with neurological involvement and hemophagocytic lymphohistiocytosis: a case report. BMC Pediatr. 2021;21(1):253.","journal-title":"BMC Pediatr"},{"issue":"4","key":"1842_CR25","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1007\/s10875-008-9192-5","volume":"28","author":"S Mamishi","year":"2008","unstructured":"Mamishi S, et al. Analysis of RAB27A gene in griscelli syndrome type 2: novel mutations including a deletion hotspot. J Clin Immunol. 2008;28(4):384\u20139.","journal-title":"J Clin Immunol"},{"issue":"5 Suppl 1","key":"1842_CR26","doi-asserted-by":"publisher","first-page":"S115","DOI":"10.1016\/j.jaad.2007.05.002","volume":"58","author":"H Onay","year":"2008","unstructured":"Onay H, et al. A further Turkish case of Griscelli syndrome with new RAB27A mutation. J Am Acad Dermatol. 2008;58(5 Suppl 1):S115\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1842_CR27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/08880010500506909","volume":"23","author":"D Aslan","year":"2006","unstructured":"Aslan D, et al. Griscelli syndrome: description of a case with Rab27A mutation. Pediatr Hematol Oncol. 2006;23(3):255\u201361.","journal-title":"Pediatr Hematol Oncol"},{"issue":"10","key":"1842_CR28","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1590\/S0100-879X2008001000002","volume":"41","author":"IP Meschede","year":"2008","unstructured":"Meschede IP, et al. Griscelli syndrome-type 2 in twin siblings: case report and update on RAB27A human mutations and gene structure. Braz J Med Biol Res. 2008;41(10):839\u201348.","journal-title":"Braz J Med Biol Res"},{"issue":"4","key":"1842_CR29","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/sj.bmt.1703114","volume":"28","author":"F Schuster","year":"2001","unstructured":"Schuster F, et al. Griscelli syndrome: report of the first peripheral blood stem cell transplant and the role of mutations in the RAB27A gene as an indication for BMT. Bone Marrow Transpl. 2001;28(4):409\u201312.","journal-title":"Bone Marrow Transpl"},{"issue":"2","key":"1842_CR30","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1086\/341606","volume":"71","author":"Y Anikster","year":"2002","unstructured":"Anikster Y, et al. Evidence that Griscelli syndrome with neurological involvement is caused by mutations in RAB27A, not MYO5A. Am J Hum Genet. 2002;71(2):407\u201314.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"1842_CR31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1023\/B:JOCI.0000029119.83799.cb","volume":"24","author":"JC Bizario","year":"2004","unstructured":"Bizario JC, et al. Griscelli syndrome: characterization of a new mutation and rescue of T-cytotoxic activity by retroviral transfer of RAB27A gene. J Clin Immunol. 2004;24(4):397\u2013410.","journal-title":"J Clin Immunol"},{"issue":"8","key":"1842_CR32","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1177\/0883073808315409","volume":"23","author":"A Masri","year":"2008","unstructured":"Masri A, et al. Griscelli syndrome type 2: a rare and lethal disorder. J Child Neurol. 2008;23(8):964\u20137.","journal-title":"J Child Neurol"},{"issue":"4","key":"1842_CR33","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/ajmg.a.10836","volume":"116a","author":"G Aksu","year":"2003","unstructured":"Aksu G, et al. Griscelli syndrome without hemophagocytosis in an eleven-year-old girl: expanding the phenotypic spectrum of Rab27A mutations in humans. Am J Med Genet A. 2003;116a(4):329\u201333.","journal-title":"Am J Med Genet A"},{"issue":"1","key":"1842_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1179\/000349803125002896","volume":"23","author":"N Sarper","year":"2003","unstructured":"Sarper N, et al. A rare syndrome in the differential diagnosis of hepatosplenomegaly and pancytopenia: report of identical twins with Griscelli disease. Ann Trop Paediatr. 2003;23(1):69\u201373.","journal-title":"Ann Trop Paediatr"},{"issue":"4","key":"1842_CR35","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1023\/A:1016045026204","volume":"22","author":"O Sanal","year":"2002","unstructured":"Sanal O, et al. Griscelli disease: genotype-phenotype correlation in an array of clinical heterogeneity. J Clin Immunol. 2002;22(4):237\u201343.","journal-title":"J Clin Immunol"},{"issue":"10","key":"1842_CR36","doi-asserted-by":"publisher","first-page":"4306","DOI":"10.1182\/blood-2006-09-047159","volume":"109","author":"R Gazit","year":"2007","unstructured":"Gazit R, et al. NK cytotoxicity mediated by CD16 but not by NKp30 is functional in Griscelli syndrome. Blood. 2007;109(10):4306\u201312.","journal-title":"Blood"},{"issue":"4","key":"1842_CR37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.braindev.2006.09.007","volume":"29","author":"M Rajadhyax","year":"2007","unstructured":"Rajadhyax M, et al. Neurological presentation of Griscelli syndrome: obstructive hydrocephalus without haematological abnormalities or organomegaly. Brain Dev. 2007;29(4):247\u201350.","journal-title":"Brain Dev"},{"issue":"9","key":"1842_CR38","first-page":"944","volume":"41","author":"SR Sheela","year":"2004","unstructured":"Sheela SR, Latha M, Injody SJ. Griscelli syndrome: Rab 27a mutation. Indian Pediatr. 2004;41(9):944\u20137.","journal-title":"Indian Pediatr"},{"issue":"2","key":"1842_CR39","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.ymgme.2008.02.009","volume":"94","author":"W Westbroek","year":"2008","unstructured":"Westbroek W, et al. A novel missense mutation (G43S) in the switch I region of Rab27A causing Griscelli syndrome. Mol Genet Metab. 2008;94(2):248\u201354.","journal-title":"Mol Genet Metab"},{"issue":"5","key":"1842_CR40","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/j.1600-0749.2004.00173.x","volume":"17","author":"W Westbroek","year":"2004","unstructured":"Westbroek W, et al. Rab27b is up-regulated in human Griscelli syndrome type II melanocytes and linked to the actin cytoskeleton via exon F-Myosin va transcripts. Pigment Cell Res. 2004;17(5):498\u2013505.","journal-title":"Pigment Cell Res"},{"issue":"11","key":"1842_CR41","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1002\/ajmg.a.61829","volume":"182","author":"R Al-Sulaiman","year":"2020","unstructured":"Al-Sulaiman R, et al. A founder RAB27A variant causes Griscelli syndrome type 2 with phenotypic heterogeneity in Qatari families. Am J Med Genet A. 2020;182(11):2570\u201380.","journal-title":"Am J Med Genet A"},{"issue":"4","key":"1842_CR42","first-page":"193","volume":"69","author":"H Ariffin","year":"2014","unstructured":"Ariffin H, et al. Griscelli syndrome. Med J Malaysia. 2014;69(4):193\u20134.","journal-title":"Med J Malaysia"},{"issue":"7","key":"1842_CR43","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/MPH.0b013e31826781ad","volume":"34","author":"A Durmaz","year":"2012","unstructured":"Durmaz A, et al. Molecular analysis and clinical findings of Griscelli syndrome patients. J Pediatr Hematol Oncol. 2012;34(7):541\u20134.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"7","key":"1842_CR44","first-page":"612","volume":"20","author":"BS Shamsian","year":"2010","unstructured":"Shamsian BS, et al. A novel RAB27A mutation in a patient with Griscelli syndrome type 2. J Investig Allergol Clin Immunol. 2010;20(7):612\u20135.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"4","key":"1842_CR45","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1007\/s12519-017-0037-2","volume":"13","author":"P Yeetong","year":"2017","unstructured":"Yeetong P, Suphapeetiporn K, Shotelersuk V. Mutation analysis and prenatal diagnosis of a family with Griscelli syndrome type 2: two novel mutations in the RAB27A gene. World J Pediatr. 2017;13(4):392\u20134.","journal-title":"World J Pediatr"},{"issue":"1","key":"1842_CR46","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/humu.20274","volume":"27","author":"U Zur Stadt","year":"2006","unstructured":"Zur Stadt U, et al. Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A. Hum Mutat. 2006;27(1):62\u20138.","journal-title":"Hum Mutat"},{"issue":"10","key":"1842_CR47","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1002\/humu.23274","volume":"38","author":"V Grandin","year":"2017","unstructured":"Grandin V, et al. A RAB27A duplication in several cases of Griscelli syndrome type 2: an explanation for cases lacking a genetic diagnosis. Hum Mutat. 2017;38(10):1355\u20139.","journal-title":"Hum Mutat"},{"issue":"2","key":"1842_CR48","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3345\/kjp.2014.57.2.91","volume":"57","author":"K Mishra","year":"2014","unstructured":"Mishra K, et al. Griscelli syndrome type 2: a novel mutation in RAB27A gene with different clinical features in 2 siblings: a diagnostic conundrum. Korean J Pediatr. 2014;57(2):91\u20135.","journal-title":"Korean J Pediatr"},{"issue":"1","key":"1842_CR49","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ymgme.2010.05.015","volume":"101","author":"LM Vincent","year":"2010","unstructured":"Vincent LM, et al. Novel 47.5-kb deletion in RAB27A results in severe Griscelli syndrome type 2. Mol Genet Metab. 2010;101(1):62\u20135.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"1842_CR50","first-page":"113","volume":"59","author":"R Rajyalakshmi","year":"2016","unstructured":"Rajyalakshmi R, Chakrapani RN. Griscelli syndrome type 2: a rare and fatal syndrome in a south Indian boy. Indian J Pathol Microbiol. 2016;59(1):113\u20136.","journal-title":"Indian J Pathol Microbiol"},{"issue":"1","key":"1842_CR51","doi-asserted-by":"publisher","first-page":"76","DOI":"10.5582\/irdr.2016.01084","volume":"6","author":"P Minocha","year":"2017","unstructured":"Minocha P, et al. Griscelli syndrome subtype 2 with hemophagocytic lympho-histiocytosis: a case report and review of literature. Intractable Rare Dis Res. 2017;6(1):76\u20139.","journal-title":"Intractable Rare Dis Res"},{"issue":"6","key":"1842_CR52","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/scd.12328","volume":"38","author":"N Tewari","year":"2018","unstructured":"Tewari N, et al. Oral features of Griscelli syndrome type II: a rare case report. Spec Care Dentist. 2018;38(6):421\u20135.","journal-title":"Spec Care Dentist"},{"issue":"1","key":"1842_CR53","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1111\/pde.14370","volume":"38","author":"R Gotesman","year":"2021","unstructured":"Gotesman R, et al. Cutaneous granulomas as the presenting manifestation of Griscelli syndrome type 2. Pediatr Dermatol. 2021;38(1):194\u20137.","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"1842_CR54","first-page":"488","volume":"21","author":"H Nodehi","year":"2022","unstructured":"Nodehi H, et al. Neonatal onset of Hemophagocytic Lymphohistiocytosis due to prenatal varicella-zoster infection in a neonate with Griscelli Syndrome Type 2. Iran J Allergy Asthma Immunol. 2022;21(4):488\u201393.","journal-title":"Iran J Allergy Asthma Immunol"},{"key":"1842_CR55","doi-asserted-by":"crossref","unstructured":"Gironi LC et al. Congenital Hypopigmentary disorders with Multiorgan Impairment: a Case Report and an overview on Gray Hair syndromes. Med (Kaunas), 2019. 55(3).","DOI":"10.3390\/medicina55030078"},{"issue":"6","key":"1842_CR56","doi-asserted-by":"publisher","first-page":"e13034","DOI":"10.1111\/sji.13034","volume":"93","author":"LM Casta\u00f1o-Jaramillo","year":"2021","unstructured":"Casta\u00f1o-Jaramillo LM, et al. Diagnostic and therapeutic caveats in Griscelli syndrome. Scand J Immunol. 2021;93(6):e13034.","journal-title":"Scand J Immunol"},{"issue":"8","key":"1842_CR57","doi-asserted-by":"publisher","first-page":"e28312","DOI":"10.1002\/pbc.28312","volume":"67","author":"KE Woodward","year":"2020","unstructured":"Woodward KE, et al. Considering immunologic and genetic evaluation for HLH in neuroinflammation: a case of Griscelli syndrome type 2 with neurological symptoms and a lack of albinism. Pediatr Blood Cancer. 2020;67(8):e28312.","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"1842_CR58","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.jaci.2018.02.031","volume":"142","author":"B Tesi","year":"2018","unstructured":"Tesi B, et al. A RAB27A 5\u2019 untranslated region structural variant associated with late-onset hemophagocytic lymphohistiocytosis and normal pigmentation. J Allergy Clin Immunol. 2018;142(1):317\u2013e3218.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"1842_CR59","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1755-148X.2010.00705.x","volume":"23","author":"N Ohbayashi","year":"2010","unstructured":"Ohbayashi N, et al. Functional characterization of two RAB27A missense mutations found in Griscelli syndrome type 2. Pigment Cell Melanoma Res. 2010;23(3):365\u201374.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"3","key":"1842_CR60","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1111\/j.1540-9740.2007.05783.x","volume":"6","author":"PO Emanuel","year":"2007","unstructured":"Emanuel PO, Sternberg LJ, Phelps RG. Griscelli Syndrome Skinmed. 2007;6(3):147\u20139.","journal-title":"Griscelli Syndrome Skinmed"},{"issue":"6","key":"1842_CR61","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1080\/08880018.2021.1895925","volume":"38","author":"YH Messinger","year":"2021","unstructured":"Messinger YH, et al. Delayed diagnosis of Griscelli syndrome type 2 with compound heterozygote RAB27A variants presenting with pulmonary failure. Pediatr Hematol Oncol. 2021;38(6):593\u2013601.","journal-title":"Pediatr Hematol Oncol"},{"issue":"4","key":"1842_CR62","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1159\/000203646","volume":"218","author":"A Rossi","year":"2009","unstructured":"Rossi A, et al. Griscelli syndrome type 2: long-term follow-up after unrelated donor bone marrow transplantation. Dermatology. 2009;218(4):376\u20139.","journal-title":"Dermatology"},{"issue":"5","key":"1842_CR63","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.pediatrneurol.2015.01.010","volume":"52","author":"I Panigrahi","year":"2015","unstructured":"Panigrahi I, et al. Seizure as the presenting manifestation in Griscelli syndrome type 2. Pediatr Neurol. 2015;52(5):535\u20138.","journal-title":"Pediatr Neurol"},{"issue":"4","key":"1842_CR64","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1111\/bjd.14866","volume":"176","author":"JYW Lee","year":"2017","unstructured":"Lee JYW, et al. Further evidence for genotype-phenotype disparity in Griscelli syndrome. Br J Dermatol. 2017;176(4):1086\u20139.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1842_CR65","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/MPH.0000000000000234","volume":"37","author":"A Hinson","year":"2015","unstructured":"Hinson A, et al. Congenital hemophagocytic lymphohistiocytosis presenting as thrombocytopenia in a newborn. J Pediatr Hematol Oncol. 2015;37(4):300\u20133.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"6","key":"1842_CR66","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1089\/vim.2011.0034","volume":"24","author":"A Szczawinska-Poplonyk","year":"2011","unstructured":"Szczawinska-Poplonyk A, et al. Pulmonary lymphomatoid granulomatosis in Griscelli syndrome type 2. Viral Immunol. 2011;24(6):471\u20133.","journal-title":"Viral Immunol"},{"issue":"4","key":"1842_CR67","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1002\/pbc.22357","volume":"54","author":"M Meeths","year":"2010","unstructured":"Meeths M, et al. Clinical presentation of Griscelli syndrome type 2 and spectrum of RAB27A mutations. Pediatr Blood Cancer. 2010;54(4):563\u201372.","journal-title":"Pediatr Blood Cancer"},{"key":"1842_CR68","doi-asserted-by":"publisher","first-page":"1151166","DOI":"10.3389\/fimmu.2023.1151166","volume":"14","author":"N Brauer","year":"2023","unstructured":"Brauer N, et al. Immunodeficiency with susceptibility to lymphoma with complex genotype affecting energy metabolism (FBP1, ACAD9) and vesicle trafficking (RAB27A). Front Immunol. 2023;14:1151166.","journal-title":"Front Immunol"},{"issue":"2","key":"1842_CR69","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/bioinformatics\/bts658","volume":"29","author":"M Silberstein","year":"2013","unstructured":"Silberstein M, et al. A system for exact and approximate genetic linkage analysis of SNP data in large pedigrees. Bioinformatics. 2013;29(2):197\u2013205.","journal-title":"Bioinformatics"},{"issue":"6","key":"1842_CR70","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1365-2141.2010.08289.x","volume":"150","author":"RD Wheeler","year":"2010","unstructured":"Wheeler RD, et al. A novel assay for investigation of suspected familial haemophagocytic lymphohistiocytosis. Br J Haematol. 2010;150(6):727\u201330.","journal-title":"Br J Haematol"},{"key":"1842_CR71","doi-asserted-by":"publisher","first-page":"1326489","DOI":"10.3389\/fped.2024.1326489","volume":"12","author":"E Elgaali","year":"2024","unstructured":"Elgaali E, et al. Genetic background of primary and familial HLH in Qatar: registry data and population study. Front Pediatr. 2024;12:1326489.","journal-title":"Front Pediatr"},{"issue":"5","key":"1842_CR72","doi-asserted-by":"publisher","first-page":"5","DOI":"10.5070\/D30FB7F671","volume":"9","author":"NS Scheinfeld","year":"2003","unstructured":"Scheinfeld NS. Syndromic albinism: a review of genetics and phenotypes. Dermatol Online J. 2003;9(5):5.","journal-title":"Dermatol Online J"},{"issue":"7","key":"1842_CR73","doi-asserted-by":"publisher","first-page":"e13040","DOI":"10.1111\/petr.13040","volume":"21","author":"B Kuskonmaz","year":"2017","unstructured":"Kuskonmaz B, et al. Hematopoietic stem cell transplantation in children with Griscelli syndrome: a single-center experience. Pediatr Transplant. 2017;21(7):e13040.","journal-title":"Pediatr Transplant"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-024-01842-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10875-024-01842-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10875-024-01842-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T17:02:06Z","timestamp":1777309326000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10875-024-01842-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,28]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1842"],"URL":"https:\/\/doi.org\/10.1007\/s10875-024-01842-2","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,28]]},"assertion":[{"value":"20 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr Lim reported receiving personal fees from Octapharma, Roche, Novartis, and Amgen. All other authors have no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"50"}}